estimated to affect 170 million people worldwide and 20%-30% of these will eventually progress to liver cirrhosis and its sequelae, such as hepatocellular carcinoma.1 In the Kingdom of Saudi Arabia (KSA) sero-prevalence studies suggest that the overall antiHCV positivity is 0.99%, while in subjects over the age of 50 years it is 3.5%-5%.2,3 This prevalence rises to 75% among intravenous drug us...